The Future in Cannabis. WorldWide.

News

DEVELOPING THE BLUEPRINT FOR THE DIGITAL CANNABIS ECONOMY

TheraCann International and Tokes Platform to provide blockchain based “provenance” features into seed-to-sale ERP and Merchant Gateway

Calgary, Alberta Canada – February 8th, 2018 – TheraCann International Benchmark Corporation, a leading full service international cannabis business and technology firm (“TheraCann”) and Tokes Platform (“Tokes”), a leader in providing blockchain solutions for the cannabis industry, released this week they have begun the full-scale development of adding blockchain based “provenance” features into the FinCEN compliant cannabis seed-to-sale Enterprise Resource Platform (ERP), TheraCannSYSTEM™. This ERP blockchain development includes integration of cryptocurrency payment features via the Tokes Platform merchant gateway and integration with TheraCann’s molecular tagging system to create an immutable link between the authenticity of goods and the authenticity of digital transactions throughout the supply chain.

“This is groundbreaking,” Gabriel Allred, co-founder of Tokes Platform, says “For the first time a cryptocurrency blockchain has been integrated within a piece of functional resource management software. Being integrated up the verticals and across businesses will revolutionize how cannabis businesses transact.”
The global cannabis economy is expected to reach $140 Billion in the next 10 years with new legal medicinal and recreational legislation introduced seemingly each month. Combining blockchain, manufacturing control and molecular traceability within an existing seed to sale system provides provincial, state and international lawmakers a new blueprint to build and develop comprehensive guidelines, now and in the future.

Chris Bolton, Chief Operating Officer of TheraCann International, says “The ability to provide a platform for cannabis producers, processors, distributors, retailers, laboratories, government, law enforcement and all ancillary verticals along the supply chain with both batch and forensic origination control, all the while ensuring the veracity within a distributed ledger, was basically science fiction only a few years ago. Our partnership with the Tokes Platform allows TheraCann to develop these solutions for the global cannabis market today.”

###

About TheraCann International Benchmark Corporation
Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace. TheraCann provides business, technology and industry experts who apply advanced technology and help clients design, build and run their cannabis businesses. With nearly 3.5 million square feet of cannabis operations under management and the successful launch of groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and patented genetic tracking and diversion prevention systems, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements. More information about TheraCann is available at www.theracanncorp.com.

About Tokes Platform
The Tokes Platform is a digital currency and software development company focused on the legal cannabis industry. Tokes’ core initiatives include a blockchain-based e-payment solutions, industry agnostic point-of-sale software, as well as compliance and provenance management through a dedicated ERP seed-to-sale application. The ERP enables external developer integration through a modular design and improves regulatory compliance through transparency of payments and supply chain management. More details about the company available at www.tokesplatform.org

TheraCann International and Applied DNA Sciences Complete Cannabis Tracking Trial

STONY BROOK, N.Y.–(BUSINESS WIRE)–Applied DNA Sciences, Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”) announced today that in conjunction with TheraCann International Benchmark Corporation, it has had early success in the tagging and authentication of legal cannabis and its derivatives in a laboratory pilot. The pilot demonstrated that after a single application of Applied DNA’s molecular taggants to cannabis plants during their growth stage, the taggants are detectable in processed trimmed cannabis, extracted cannabis oils and derivative products later produced from the tagged cannabis plants.

“These early pilot results provide us confidence that our combined expertise will produce a seed-to-sale solution that will provide an unparalleled level of transparency for growers, processors and dispensaries,” said Richard Goodman, President of TheraCann’s Tracking Technology Division. “Our solution will enable all members of the cannabis supply chain to conduct their own testing and prove, with scientific certainty, that their products are originating from their facilities or other legal sources.”

“The ability for our molecular taggants to be detected throughout all points in the legal cannabis supply chain, and for the tagged product(s) to be forensically analyzed, is an important strategic advantage for our platform,” said Gordon Hope, Director of Cannabis Markets at Applied DNA. “We are encouraged by these initial pilot study results, as we expect that our taggants will serve as a unique forensic identifier that becomes part of a blockchain transaction throughout the legal cannabis supply chain.”

In January 2018, Applied DNA and TheraCann announced an initial two-year, $1 million contract for the integration of the Applied DNA’s SigNature® molecular tagging and testing technology into TheraCann’s blockchain-based, seed-to-sale Enterprise Resource Platform (ERP) for legal cannabis operations. Applied DNA will develop the technologies necessary to tag and authenticate legal cannabis throughout the supply chain and seamlessly integrate tagging and authentication data into TheraCann’s ERP and blockchain platform.

This new platform is expected to be the first system of its kind to include molecular track-and-trace built on a powerful blockchain backbone for the management and tracking of legal cannabis and derivative products within the industry. Whereas broader and expanded testing is still to be performed, this is a significant milestone toward the eventual commercialization of the combined cannabis system.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics. The Company makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

The proprietary DNA-based CertainT® platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac® and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

About TheraCann International Benchmark Corporation

Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace. TheraCann provides business, technology and industry experts who apply advanced technology and help clients design, build and run their cannabis businesses. With nearly 5 million square feet of cannabis operations under management and the successful launch of groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and patented genetic tracking and diversion prevention systems, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements.

More information about TheraCann is available at www.theracanncorp.com. Follow TheraCann on Twitter and LinkedIn.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, shifting enforcement priorities of US federal laws relating to cannabis, market competition and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017, which is available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Security Updates from the Health Canada for existing and potential Licenced Producers

On January 25, 2018, Health Canada updated the security requirements for Licenced Producers under the Access to Cannabis for Medical Purposes Regulations (ACMPR). This amendment to the regulations makes substantive changes to the storage area(s) for current licensed producers and applicants, including re-classification of which was previously the ‘vault’.  As per the Security Directive the vault is now generically defined to be a ‘secure rooms or areas’. There are also impacts on the requirement for cameras within controlled areas such as grow rooms.

For the “secure room” the minimum requirements are as follows:

  • The security that was previously required for the VAULT by way of intrusion system and sensors is to be maintained. This includes full and detailed video surveillance that works in all conditions, and access control for all entry/exit points that logs and records all person(s).
  • The secure room is no longer required to have ‘free and clear’ space on all sides and ceiling as per the regulations but needs to be physically built to prevent unauthorized entry through the entry/exit points and walls/ceiling/floor, as well as allow ‘good production practices’ for a clean zone.
  • The secure room must be constructed in a manner that allows for ‘good business practices’ for the cleanliness and ability to sterilize the area.
  • Either the RPIC or A/RPIC must be present when work is conducted in secure areas. Only person(s) required to be in the storage area(s) for their work are allowed.
  • The new regulations specifically removes the requirement for 24/7 visual monitoring/recording.

Although HC has reduced the requirement for security, there are additional considerations that must be reviewed at time of construction:

  • Insurance underwriters have strongly signalled that they will adopt the model used for the jewellery industry. This means the higher the value or risk area or history of the site/business, the higher the insurance premiums will be. Premium are, in part, linked to the sophistication of the security system and the ability of the business to protect itself against disruption or theft.

HC has yet to determine the “standard” physical requirements of the storage room(s), but it is clear that the materials used must prevent unauthorized entry through the doors, walls, ceiling or floor. This will require the room(s) to be constructed of a hardened material and the doors and door frames of commercial grade steel at a minimum.

Applied DNA Sciences together with TheraCann International Will Create the First Seed-to-Sale Cannabis Tracking System Combining Molecular Tagging and Blockchain Technologies

STONY BROOK N.Y. (January 25th, 2018)Applied DNA Sciences, Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”) today announced the signing of an initial two-year, $1 million contract with TheraCann International Benchmark Corporation, (“TheraCann”), a leading full service cannabis consultancy with operations in the US, Canada, Australia, Europe and South America, for the integration of the Company’s SigNature® molecular tagging and testing technology into TheraCann’s blockchain-based, seed-to-sale Enterprise Resource Platform (ERP) for legal cannabis operations. Under the terms of the contract, the companies have entered into a development and marketing agreement whereby Applied DNA will develop the technologies necessary to tag and authenticate legal cannabis throughout the supply chain and seamlessly integrate tagging and authentication data into TheraCann’s ERP and Blockchain platform. Applied DNA will receive an initial payment under its contract with TheraCann in the current quarter.

 

The rapid global adoption of legal cannabis legislation has accelerated the need to secure and truly validate cannabis supply chains from seed-to-sale. Current systems, many of which rely on RFID or bar code technologies, are capable of accurately tacking cannabis supply chains through the cultivation stage, but cannot forensically track cannabis and/or cannabis derivative products back to a specific source once the physical tags and packaging are removed. This gap allows the opportunity for illegal diversion and the introduction of illegally-sourced cannabis into legal supply chains. Combining molecular tagging with digital tracking enhances existing seed to sale systems to a new level of capability and compliance with state, and international laws and guidelines.

 

In response to the known limitations of current seed-to-sale systems, the State of Colorado this month introduced a new bill (SB 18-029) that mandates the addition of physical-chemical identifiers (PCIDs), of which Applied DNA’s molecular tags comply, to all legal cannabis plants grown in the state for the purposes of tracking cannabis and cannabis derivative products back to their origin. As the industry matures, next generation platforms, such as the one under development by Applied DNA and TheraCann, will support collaboration between regulators, law enforcement and producers in shaping the future of the cannabis industry.

 

“Our molecular tag creates an immutable link between the authenticity of goods and the authenticity of digital transactions to serve as a unique and forensic identifier that becomes part of a blockchain transaction throughout the supply chain,” stated Dr. James A. Hayward, president and chief executive officer of Applied DNA. “We believe that all blockchain platforms require forensic origination to ensure the veracity of the subsequent distributed ledger. The legal global cannabis industry is a complex supply chain and, therefore, a natural fit for our proven technologies across all medical and consumer applications. We are excited to work with TheraCann to enhance traceability in the expanding legal cannabis market.”

 

According to a market report from Arcview Research, the North American legal cannabis market in 2017 was valued at $6.7 billion per year and is expected to grow to $20.1 billion per year by 2021. While cannabis remains illegal under US federal law, eight states plus Washington DC have legalized cannabis for recreational use, while twenty-nine states plus Washington DC have legalized cannabis for medical use. An additional seven states are expected to legalize cannabis in the coming year[1]. 15 countries outside the USA have permitted medical cannabis.  Canada has been operating a federal medical cannabis program since 2001 and is expected to federally legalize recreational cannabis by mid-2018[2].

 

Chris Bolton, Chief Operating Officer for TheraCann added, “The platform under development by TheraCann and Applied DNA will be uniquely suited to meet the growing demand for true forensic level seed-to-sale tracking and diversion control systems globally. As each new state or country legalizes medicinal or recreational cannabis, it creates an opportunity for the broad-scale adoption of our technologies.”

 

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics. The Company makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

The proprietary DNA-based CertainT® platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac® and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

 

About TheraCann International Benchmark Corporation

Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace including, government applications, planning, facility design, cultivation, marketing and communications. With nearly 5 million square feet of cannabis operations under management and the successful launch of groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and integrated finCEN compliant blockchain solutions, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements.

 

More information about TheraCann is available at www.theracanncorp.com. Follow TheraCann on Twitter and Linkedin.

[1] https://www.forbes.com/sites/tomangell/2017/12/26/these-states-are-likely-to-legalize-marijuana-in-2018/2/#73b90f161b04

[2] https://globalnews.ca/news/3867467/marijuana-legalization-canada-progress/

TheraCann and Maple Leaf Green World Settlement Agreement

Calgary, Alberta Canada – January 2nd, 2018 – TheraCann International Benchmark Corporation, a leading full service international cannabis consultancy (“TheraCann”), announced today TheraCann Canada a wholly owned subsidiary of TheraCann International Benchmark Corporation and Maple Leaf Green World Ltd. (MLGW) have settled all litigation related to their licencing and service dispute. This settlement ends all ongoing claims between the parties while mutually agreeing to hold each other harmless in any future actions. The terms of the agreement are confidential.

###

About TheraCann International Benchmark Corporation

Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace including, government applications, planning, facility design, cultivation, marketing and communications. With nearly 5 million square feet of cannabis operations under management and the successful launch of groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and genetic diversion prevention systems, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements. More information about TheraCann is available at www.theracanncorp.com.

Tokes​ ​Platform​ ​and​ ​TheraCann​ ​International​ ​Announce​ ​Strategic​ ​Partnership​ ​to Build​ ​Solutions​ ​for​ ​the​ ​Cannabis​ ​Industry

Las Vegas, Nevada – December 21th, 2017 – Tokes Platform, a leader in providing blockchain solutions
for the cannabis industry, and TheraCann International Benchmark Corporation, a leading full service
international cannabis consultancy (“TheraCann”), is pleased to announce today they have entered into
a strategic partnership.

Chris Bolton, chief operating officer of TheraCann International, says “We were impressed early on with
Tokes innovative approaches towards very real and much needed solutions. Our joint projects and
ventures are well positioned to be game changers in the ever evolving cannabis industry. We are looking
forward to presenting the products of our partnership in early 2018.”

###

About TheraCann International Benchmark Corporation
Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service
solution for the International cannabis marketplace including, government applications, planning, facility
design, cultivation, marketing and communications. With nearly 5 million square feet of cannabis
operations under management and the successful launch of groundbreaking Enterprise Resource
Planning (ERP) software, Aeroponic cultivation systems and genetic diversion prevention systems,
TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements.
More information about TheraCann is available at www.theracanncorp.com.

About Tokes Platform
The Tokes Platform was founded to solve the legal cannabis industry’s cash-only transaction and banking
issues with their cryptocurrency Tokes ($TKS), as well as their software solutions for payment processing
and supply chain management. Running on the Waves blockchain, Tokes are a robust cryptocurrency
with fast transaction times (less than a minute) and a secure immutable digital ledger. The Tokes
transactional protocol is applicable for both business-to-business and consumer-to-business models.
More information about Tokes Platform is available at https://tokesplatform.org.

Press Contacts:
Sabrina Chapman, Public Relations Director for Tokes Platform, Perspective Marketing
Email: sabrina@findingperspectives.com ; Cell: 540-514-0638

Jason Warnock
Managing Director, TheraCann Capital, TheraCann International
Email: jwarnock@theracanncorp.com

Proposed Approach to the Regulation of Cannabis in Canada

The Canadian government announced on November 21st, a proposed approach to expand the regulatory framework for cannabis cultivation, processing and potential product uses. Health Canada is proposing to build upon established regulatory requirements that have long been in place for current producers of cannabis and add a number of smaller and ancillary licences including, micro-cultivation, micro-processing and nursery licences. Micro-cultivation for example is to allow small scale growers the ability to produce cannabis with THC less than 0.3%. The proposed regulations also allow for the cultivation of industrial hemp and a potential framework for retail medical and non-medical sale licences.

The proposed changes will also potentially impact the current and future ACMPR Licenced Producers (LPs) in terms of onsite security. The changes include; LPs would no longer require cannabis to be stored in accordance with the Directive on Physical Security Requirements for Controlled Substances (Security Requirements for Licensed Dealers for the Storage of Controlled Substances). Second, the proposed regulations would require visual recordings to be kept for one year, rather than for two years. Based on experience with the current program, this period of time is considered to be sufficient for compliance and enforcement purposes. Third, the proposed regulations would not require visual monitoring of areas where cannabis is grown. Considering the lower risk of theft of whole plants compared to processed material, other physical security requirements respecting cultivation areas (such as visual monitoring of the perimeter and points of entry) are considered to be sufficient mitigation against the risk of theft. Finally, the proposed regulations would no longer require the presence of a security-cleared individual when others are in an area where cannabis is present.

The government will be soliciting public input and views on the approach to these new regulations until January 20th, 2018. Health Canada encourages all interested parties to provide feedback online. For more information regarding the public consultation process, please see: www.canada.ca/en/health-canada/programs/consultation-proposed-approach-regulation-cannabis.html.

Global interest grows in the Aussie cannabis market

Article from Dopamine (June 7th) – Australia’s premier online cannabis lifestyle title and features everything from weed culture to music, gaming, food and more.

We caught up with founder Chris Bolton at the Hemp Health and Innovation Expo to talk about TheraCann and the future of the Australian cannabis industry,

So, what is TheraCann, and why does the team care about Australia?

Essentially, it’s a consultancy service specifically tailored for the cannabis industry:

“TheraCann provides full turn-key solutions to anyone looking to enter the cannabis space in an industrial scale,” explains Chris, “so being able to ensure all quality of production, right through to regulatory compliance.

“We provide the plans, the design, we implement [including building the facility], bring in all the equipment, provide all the training, then we provide all the ongoing support.”

In other words, they handle the nitty gritty side of running a cannabis business (medical or recreational) so that you don’t have to worry about the tedious elements such as licensing and regulatory compliance.

What strikes me most when talking to Chris, however, is his interest in and enthusiasm for the Australian medicinal market: one that – for all appearances – is in total infancy.

“We’re here at this fantastic trade show in Australia because we see this as the next opportunity globally,” he says. “We operate in five countries worldwide that are licensed and Australia is at the tipping point in our personal opinion.”

What makes him say that of a country who only just implemented the barest of medicinal policies?

“Well, we look at the number patients purportedly consuming on a daily, weekly schedule. Australia outpaces Canada at a factor of 1.5 for that. So you have more users right now in Australia than we do in Canada which has a full, thriving, medical community.”

It might come as a bit of a surprise to hear that – it did to me – and it means that the need for our medical industry to grow is even more pressing. 

“If we look at the patient, they just want to get well, but they have to find a doctor knowledgable enough to prescribe what they need – the right cannabis strain, or mix of THC/CBD or other constituent products in the cannabis stream that will make them well.”

Right now we don’t have that. So, although we already have the patient base, there are still a few steps left before we’re in the position we need to be: a few official boxes to be ticked and a few frameworks put in place.

The value of talking to somebody like Chris is that he’s seen it all before with the growth of the Canadian cannabis industry and knows what needs to happen.

The first stage is a functioning and reliable medicinal industry:

“Obviously you need the final approval at a state-wide level … but you also need to have a consistent, cohesive plan how doctors can comfortably prescribe product to patients … There’s always been a gap in most regulatory frameworks that connect the right patient to the right doctor, the doctor to the right producer, and the feedback loop between the patient and the producer … That dialogue has to be a tri-way discussion, and in markets that are successful, that’s the missing part. Once that comes together you’ll find that it blows the door open.”

The second step, according to Chris, is to prepare for the advent of a recreational market.

“You have to now start to think of the day when recreational becomes legal. You’re going to use the same licensed producers, under the same framework, for quality assurance, record keeping, traceability and whatnot to provide a recreational market which is often a hundred times the size of your medical market … not having that in place in the forethought of how you’re going to manage that is the number one hurdle of any jurisdiction.”

What we want to avoid in setting up our cannabis industry is jumping the gun like Uruguay did in going from full prohibition to full legalisation without the proper preparation.

“They went full legal for medical and recreational but they cannot meet demand,” says Chris. “They can’t produce enough, so what’s happening is illicit product is coming in through the back door which is dwarfing the growth of the industry. There’s no quality assurance and their losing the tax opportunity.”

When it comes to the medicinal side of things, mistakes like this are a massive concern as they limit the patients ability to get the proper treatment and a consistent product. For the recreational smoker, this isn’t as severe considering the degree of criminality in the current prohibition market, but for overall social well-being it’s better that it’s done right. Ensuring the proper systems are put in place for patients to access medicinal cannabis is our first priority, and from there its a short walk to the development of a functioning recreational market.

How is Michigan doing with its new Medical Cannabis Laws?

For those looking to get into this “Green Rush” it is critically important that one understands that this business is not designed to accommodate the novice Medical Cannabis entrepreneur and investor.  

The Michigan Medical Cannabis Industry is being regulated by LARA the Department of Licensing and Regulated Affairs. LARA has created a special unit for the regulation of medical marijuana called the Bureau of Medical Marijuana. The Bureau of Medical Marijuana regulates the Michigan’s medical marihuana facilities and licensees, including growers, processors, transporters, provisioning centers and safety compliance facilities.  The bureau also oversees the Michigan’s patient registry program and administers the Michigan Medical Marihuana Act.

For those looking to develop a career and invest into Michigan’s Medical Cannabis Industry it is important that you are aware that the new Michigan Medial Cannabis laws have designate five classes of licenses that will be available for qualified Michigan applicants:

  1. A growers license with three classes of growers
    • Class A – people who can grow up to 500 plants,
    • Class B – people who can grow up to 1,000 plants,
    • Class C – or up to 1,500 plants.
  2. A processor license
  3. A safety compliance facility license (Lab)
  4. A secure transporter license
  5. A provisioning center license (Dispensary)

Back in January 16, 2017 a well written article “New laws in Michigan shake up the marijuana industry” by Christian Sheckler South Bend Tribune sharing with Michigan’s Medical Cannabis Patient, Caregiver, and General Public that BIG changes are coming.  These changes are important as Michigan’s registered Medical Cannabis Patients are above 2oo,ooo and climbing.  This large number of register patients drives the logic behind rolling out this Medical Cannabis Industry in a cogent and regulated way.  

In theory, depending of course on many other factors that can be considered as basic “business 101” knowledge, the current Michigan Cannabis Caregiver should have some advantages in dealing with LARA’s medical marijuana regulations.  Provided  with the proper council and advise, assuming they follow the complex and ever changing laws, this new legislation could transform the former Caregivers learned skill set into a BIG Business. If you are qualified and acquire any of the 3 proposed classes of growers licenses this could be a once in a lifetime opportunity.  It does indeed appear the grass is greener on the other side!

The Canadian Cannabis Act

The Canadian Federal government today announced the Cannabis Act to provide legal access to cannabis and to control and regulate its production, distribution and sale.

The stated objectives of the Cannabis Act are to “prevent young persons from accessing cannabis, to protect public health and public safety by establishing strict product safety and product quality requirements and to deter criminal activity by imposing serious criminal penalties for those operating outside the legal framework. The Act is also intended to reduce the burden on the criminal justice system in relation to cannabis.”

The full Act can be viewed here.

Canadian cannabis legalization bill: “An Act respecting cannabis and to amend the Controlled Drugs and Subs… by Ben Adlin on Scribd